Open access in medical journals - interview with Richard Smith Videos Super User 17 April, 2013 medical journals Bookmark this
Patients From trauma to healing: How therapy complements medication i... Trauma therapy is more than just talk – it’s an evidence-backed process that helps patients reframe, process, and recover from life-altering events.
News NEJM responds to claims of bias from Justice Department The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Digital Unicorns, AI, and the future of health: Highlights from HLTH... Deep Dive editor Eloise McLennan debriefs on the key themes, hot topics, and hallway conversations that shaped the HLTH event in Amsterdam.
Oncology Life Sciences Industry Report - Oncology Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D Partner Content 16th World ADC San Diego 2025 The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference
Digital Partner Content Axtria Ignite 2025: Leading in an Agentic Era Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face